Re-engineering T-cell membranes to promote tumour destruction. v1.1

• Research type

  Research Study

• Full title

  Re-engineering T-cell membranes to promote tumour destruction

• IRAS ID

  255930

• Contact name

  David Coe

• Contact email

  d.coe@bristol.ac.uk

• Sponsor organisation

  University of Bristol

• Duration of Study in the UK

  2 years, 0 months, 0 days

• Research summary

  We propose to use human blood from healthy volunteers to characterize the effect of artificial membrane-binding protein (AMBP) modification on the viability, phenotype and proliferative capacity of T cells (Tc) expanded in vitro, in tumour mimicking environments. We will evaluate the treated and expanded Tc for their ability to kill allogeneic and syngeneic tumour cells as well as the expression of tumour destructive cytokines such as Interferon gamma and tumour necrosis factor alpha.
  Together with concurrent experiments in murine pre-clinical models these data will provide a mechanistic insight into how a range of carefully designed artificial membrane-binding proteins will impact Tc dependent tumour cell killing. Multiple AMBP targets will be tested on Tc and the lead candidates, the ones showing the most robust tumour toxicity, will be selected to generate a unique Tc therapeutic modification strategy that can be tested in clinical trials.

• REC name

  London - Surrey Research Ethics Committee

• REC reference

  19/LO/0741

• Date of REC Opinion

  25 Jun 2019

• REC opinion

  Further Information Favourable Opinion